IDEXX LABORATORIES INC /DE

In Vitro & In Vivo Diagnostic Substances·WESTBROOK, ME·FY end 12/31·CIK 874716

Financials

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$4.3B	$3.9B	$3.7B	$3.4B	$3.2B
Gross Profit	$2.7B	$2.4B	$2.2B	$2.0B	$1.9B
Operating Income	$1.4B	$1.1B	$1.1B	$898.8M	$932.0M
Net Income	$1.1B	$887.9M	$845.0M	$679.1M	$744.8M
Operating CF	$1.2B	$929.0M	$906.5M	$543.0M	$755.5M
Capex	$124.7M	$120.9M	$133.6M	$148.8M	$119.5M
Free Cash Flow	$1.1B	$808.1M	$772.9M	$394.1M	$636.0M
Buybacks	$1.2B	$837.0M	$71.9M	$819.7M	$746.8M
Dividends	—	—	—	—	—	—

Gross Margin	61.8%	61.0%	59.8%	59.5%	58.8%
Operating Margin	31.6%	29.0%	30.0%	26.7%	29.0%
Net Margin	24.6%	22.8%	23.1%	20.2%	23.2%
FCF Margin	24.6%	20.7%	21.1%	11.7%	19.8%
R&D / Revenue	5.8%	5.6%	5.2%	7.6%	5.0%
Effective Tax	20.0%	20.0%	20.4%	21.0%	17.5%
Debt / Equity	0.51	0.67	0.89	2.41	2.36
Buybacks / FCF	115.1%	103.6%	9.3%	208.0%	117.4%

No SIC peers ingested yet. As more companies in this industry are processed, this card will surface ratio / comp / margin comparisons.